Want to see SE:SEZI full AI Analyst Report?
Senzime AB (SEZI) AI Stock Analysis
Top Page
Senzime AB
(Nasdaq OMX AB:SEZI)
The score is primarily held back by weak financial performance (deep losses and sustained cash burn) despite strong revenue scaling and a solid, low-leverage balance sheet. The latest earnings call meaningfully offsets this with improving operating momentum (higher gross margin, lower opex, improved quarterly cash burn) and reiterated near-term positive cash flow guidance. Technicals remain mixed with longer-term trend still negative, and valuation is constrained by negative earnings and no dividend data.
Senzime AB (SEZI) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 36.98M
- Dividend Yield
- ―
- Average Volume (3M)
- 543.05K
- Price to Earnings (P/E)
- -5.5
- Beta (1Y)
- 0.89
- Revenue Growth
- 18.56%
- EPS Growth
- 28.11%
- Country
- Sweden
- Employees
- 59
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Senzime AB Business Overview & Revenue Model
Company Description
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europ...
How the Company Makes Money
Senzime primarily makes money by selling its medical monitoring platforms and the associated recurring-use consumables that are required when the systems are used in clinical workflows. Revenue is generated from (1) capital equipment sales (the monit...
Senzime AB Earnings Call Summary
The call was strongly constructive. Senzime reported renewed growth, 43% sensor growth, a record 74% gross margin, lower operating expenses, materially improved EBITDA and cash flow, secured financing, and a reiterated target of positive cash flow within Q4. The main challenges were delayed U.S. deal closures, weaker monitor sales, no Q3 TetraGraph-as-a-Service contracts, ongoing market adoption work, and pending South Korean regulatory approval.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated that it is “on path to reach positive cash flow within the fourth quarter,” clarifying that this means “November and December or November or we'll see what it is,” and said this is “the first step”; it is working to drive gross margin “to be in excess of 70%,” expects “70% to 80% of our business” to be recurring revenues, with this “over time” potentially “even higher,” and said “about probably more than 50% of the business over the next 10 years is going to be OEMs”; TetraGraph-as-a-Service has “some Q4 pipeline,” the Philips projects are “progressing as planned” with no market-launch timing disclosed, and South Korea has “a couple of months left” in regulatory submission mode.
Senzime AB Financial Statement Overview
Summary
Strong top-line scaling and improving gross margin (TTM gross margin 37.1%) are positives, and the balance sheet is conservatively levered (TTM debt-to-equity 0.082) with substantial equity. However, fundamentals are still dominated by very large losses (TTM net margin -92.1%) and significant cash burn (TTM operating cash flow -70.69M; free cash flow -79.84M), keeping the financial score constrained.
Income Statement
28NegativeBalance Sheet
70PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 106.35M | 104.02M | 58.48M | 35.75M | 14.03M | 10.98M |
| Gross Profit | 39.51M | 31.19M | 20.12M | 8.41M | -384.00K | -4.92M |
| EBITDA | -71.03M | -96.59M | -95.53M | -118.82M | -118.38M | -73.22M |
| Net Income | -98.00M | -137.42M | -118.73M | -134.15M | -132.70M | -82.14M |
Balance Sheet | ||||||
| Total Assets | 315.63M | 369.81M | 426.36M | 433.54M | 322.68M | 174.62M |
| Cash, Cash Equivalents and Short-Term Investments | 28.71M | 73.97M | 100.94M | 151.01M | 26.04M | 74.87M |
| Total Debt | 20.95M | 14.01M | 22.67M | 11.47M | 13.04M | 1.63M |
| Total Liabilities | 61.34M | 65.35M | 80.51M | 58.06M | 60.78M | 24.04M |
| Stockholders Equity | 254.29M | 304.46M | 345.86M | 375.48M | 261.90M | 150.58M |
Cash Flow | ||||||
| Free Cash Flow | -79.84M | -111.84M | -126.28M | -121.73M | -141.89M | -84.30M |
| Operating Cash Flow | -70.69M | -109.10M | -105.94M | -113.91M | -136.78M | -81.33M |
| Investing Cash Flow | -13.17M | -18.10M | -20.34M | -7.82M | -4.98M | -2.97M |
| Financing Cash Flow | 5.49M | 100.81M | 68.21M | 246.51M | 92.36M | -945.00K |
Senzime AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEZI, the sentiment is Positive. The current price of 3.38 is above the 20-day moving average (MA) of 2.87, above the 50-day MA of 3.02, and below the 200-day MA of 4.09, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 66.26 is Neutral, neither overbought nor oversold. The STOCH value of 70.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SEZI.
Senzime AB Peers Comparison
Overall Rating
SE:PAX60Neutral- SE:SEZI55Neutral
SE:BACTI.B53Neutral
SE:SEDANA49Neutral
SE:ACARIX33Underperform
SE:SCIB30Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:PAX | 60Neutral | SEK 1.54B | -303.85 | -1.22% | ― | 34.05% | -144.96% |
| SE:SEZI | 55Neutral | SEK 532.17M | -5.46 | -35.44% | ― | 18.56% | 28.11% |
| SE:BACTI.B | 53Neutral | SEK 560.70M | 88.89 | 1.93% | ― | -0.51% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:SEDANA | 49Neutral | SEK 926.81M | -26.86 | -3.88% | ― | 0.42% | 15.03% |
| SE:ACARIX | 33Underperform | SEK 223.04M | -5.29 | -100.09% | ― | 65.82% | 41.28% |
| SE:SCIB | 30Underperform | SEK 174.38M | -0.78 | -303.61% | ― | 51.21% | 42.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SEZI | Senzime AB | 3.38 | -2.45 | -41.94% | |
| SE:PAX | Paxman AB | 66.30 | -1.10 | -1.63% | |
| SE:SCIB | SciBase Holding AB | 12.35 | -13.24 | -51.74% | |
| SE:BACTI.B | Bactiguard Holding AB | 16.00 | -1.00 | -5.88% | |
| SE:ACARIX | Acarix AB | 0.18 | -0.10 | -35.61% | |
| SE:SEDANA | Sedana Medical AB | 9.33 | -0.83 | -8.17% |
Senzime AB Corporate Events
Senzime Posts Strong Q3 Sensor Growth and Moves Closer to Profitability
Senzime AB reported continued strong sensor sales in the third quarter of 2026, with overall revenue up 14 percent and sensor sales themselves rising 43 percent across all regions. The company’s gross margin expanded to 74 percent from 61 perce...
Senzime Schedules Webcast and Q&A for Q3 2026 Report
Senzime AB will present its third-quarter 2026 financial report to investors, analysts, and media on October 29, underscoring its engagement with the capital markets and transparency to shareholders. The report will be released at 08:00 am CEST, foll...
Senzime Data at ANESTHESIOLOGY 2026 Bolsters Case for TetraGraph and Cost-Saving Monitoring
New data unveiled at ANESTHESIOLOGY 2026 underscores the clinical and economic value of Senzime’s TetraGraph system and quantitative neuromuscular monitoring. One large study of 9,938 surgical cases shows that TetraGraph’s automated deep-...
Senzime Unveils Predictive Neuromuscular Monitoring Suite for TetraGraph
Senzime AB, a Uppsala-based medtech firm focused on neuromuscular and perioperative monitoring, continues to expand its TetraGraph platform as demand grows for quantitative, data-driven anesthesia tools. By combining hardware, software and cloud anal...
Senzime Sticks to Q4 2026 Positive Cash Flow Target on Double-Digit Sales Growth
Senzime has reaffirmed its goal of achieving positive cash flow in the fourth quarter of 2026, even as it acknowledges challenges in fully meeting its previously set ambitious revenue growth targets for the year. Preliminary third-quarter figures poi...
Senzime Secures New Credit Facility to Drive OEM Expansion and Path to Profitability
Senzime AB has secured a new SEK 35 million non-dilutive credit facility from institutional investors, replacing its previous credit line on improved terms and reinforcing its balance sheet without adding dilution. Management says the strengthened fi...
Senzime Wins Major US Hospital Network Deal for TetraGraph Monitors
Senzime AB, a Uppsala-based medical device firm listed on Nasdaq Stockholm and OTCQX, develops and markets the TetraGraph neuromuscular monitoring system, which is deployed in more than 750 hospitals and has been used on over one million patients. Th...
Senzime Wins Exclusive Five-Year VA Contract for TetraGraph Monitoring System
Senzime has secured an exclusive five-year national supply contract for its TetraGraph quantitative neuromuscular monitoring system with the U.S. Department of Veterans Affairs, awarded via its federal distribution partner TrillaMed. The deal follows...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026